ArticleThe pharmacogenomics journal2016
The P2 promoter of the IGF1 gene is a major epigenetic locus for GH responsiveness.
Article in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Epigenetic regulation of nuclear receptors: Implications for endocrine-related diseases and therapeutic strategies.Genes & diseases · 2025Review
- Maternal behavior promotes resilience to adolescent stress in mice through a microglia-neuron axis.Nature communications · 2025Article
- The association between DNA methylation and human height and a prospective model of DNA methylation-based height prediction.Human genetics · 2024Article
- Tissue explants as tools for studying the epigenetic modulation of the GH-IGF-I axis in farmed fish.Frontiers in physiology · 2024Article
- Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R.EMBO reports · 2022Article
- GH Responsiveness Is not Correlated toFrontiers in endocrinology · 2022Article
- Exosome-Derived MicroRNAs of Human Milk and Their Effects on Infant Health and Development.Biomolecules · 2021Review
- Synergistic Effects of Milk-Derived Exosomes and Galactose onInternational journal of molecular sciences · 2021Review
- A functional context for heterogeneity of the circadian clock in cells.PLoS biology · 2020Article
- A Genome-Wide Pharmacogenetic Study of Growth Hormone Responsiveness.The Journal of clinical endocrinology and metabolism · 2020Observational
- IGF1 gene is epigenetically activated in preterm infants with intrauterine growth restriction.Clinical epigenetics · 2020Article
- Regulation of gene expression by growth hormone.Molecular and cellular endocrinology · 2020Review
- Complex Phenotypes: Mechanisms Underlying Variation in Human Stature.Current osteoporosis reports · 2019Review
- Genome-wide methylation study of whole blood cells DNA in men with congenital hypopituitarism disease.International journal of molecular medicine · 2019Article
- Quantifying promoter-specific Insulin-like Growth Factor 1 gene expression by interrogating public databases.Physiological reports · 2019Article
- Milk's Role as an Epigenetic Regulator in Health and Disease.Diseases (Basel, Switzerland) · 2017Review
- Perinatal high methyl donor alters gene expression in IGF system in male offspring without altering DNA methylation.Future science OA · 2017Article
- The role of epigenomics in personalized medicine.Expert review of precision medicine and drug development · 2017Article
- Genomic insights into growth and its disorders: an update.Current opinion in endocrinology, diabetes, and obesity · 2016Review
- Genetic and Epigenetic Modulation of Growth Hormone Sensitivity Studied With the IGF-1 Generation Test.The Journal of clinical endocrinology and metabolism · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short children using growth hormone (GH) to accelerate their growth respond to this treatment with a variable efficacy. The causes of this individual variability are multifactorial and could involve epigenetics. Quantifying the impact of epigenetic variation on response to treatments is an emerging challenge. Here we show that methylation of a cluster of CGs located within the P2 promoter of the insulin-like growth factor 1 (IGF1) gene, notably CG-137, is inversely closely correlated with the response of growth and circulating IGF1 to GH administration. For example, variability in CG-137 methylation contributes 25% to variance of growth response to GH. Methylation of CGs in the P2 promoter is negatively associated with the increased transcriptional activity of P2 promoter in patients' mononuclear blood cells following GH administration. Our observation indicates that epigenetics is a major determinant of GH signaling (physiology) and of individual responsiveness to GH treatment (pharmacoepigenetics).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.